Samuel Lazzarin

Dr. Samuel Lazzarin

Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2022 in Viruses
Verified
Journal Article
Open access
PDF file
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
CVCarla della Ventura
Carla della Ventura
Stefano MenzoStefano Menzo
Stefano Menzo
BBBianca Bruzzone
Bianca Bruzzone
SGSARS-CoV- ITALIAN RESEARCH ENTERPRISE–(SCIRE) Collaborative Group
SARS-CoV- ITALIAN RESEARCH ENTERPRISE–(SCIRE) Collaborative Group
SARS-CoV-2 is constantly evolving, leading to new variants. We analysed data from 4400 SARS-CoV-2-positive samples in order to pursue epidemiological variant surveillance and to evaluate their impact on public health in Italy in the period of April–December 2021. The main circulating strain (76.2%) was the Delta variant, followed by the Alpha (13.3%), the Omicron (5.3%), and the Gamma variants (2.9%). The B.1.1 lineages, Eta, Beta, Iota, Mu, and Kappa variants, represented around 1% of cases. There were 48.2% of subjects who had not been vaccinated, and they had a lower median age compared to the vaccinated subjects (47 vs. 61 years). An increasing number of infections in the vaccinated subjects were observed over time, with the highest proportion in November (85.2%). The variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed with the Delta variant, while subjects harbouring the Gamma variant showed the highest proportion of asymptomatic infection (21.6%), albeit also deaths (5.4%). The Omicron variant was only found in the vaccinated subjects, of which 47% had been hospitalised. The diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at the national and international levels. Our study provides data on the rapid changes in the epidemiological landscape of the SARS-CoV-2 variants in Italy.

10 January 2024 in Journal of Medical Virology
Verified
Journal Article
Closed access
ARAlberto Rizzo
Alberto Rizzo
DMDavide Moschese
Davide Moschese
FSFederica Salari
Federica Salari
AGAndrea Giacomelli
Andrea Giacomelli
LMLoriana Morelli
Loriana Morelli
GRGiuliano Rizzardini
Giuliano Rizzardini

2 October 2025 in Eurosurveillance
Verified
Journal Article
Open access
DMDavide Moschese
Davide Moschese
RERozenn Esvan
Rozenn Esvan
CFChiara Fusetti
Chiara Fusetti
VBVirginia Barchi
Virginia Barchi
Maria Vittoria CossuMaria Vittoria Cossu
Maria Vittoria Cossu
valentina mazzottavalentina mazzotta
valentina mazzotta
Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.

12 June 2024 in Viruses
Verified
Journal Article
Open access
PDF file
DMDavide Moschese
Davide Moschese
SLSamuel Lazzarin
Samuel Lazzarin
MCMartina Colombo
Martina Colombo
FCFrancesco Caruso
Francesco Caruso
AGAndrea Giacomelli
Andrea Giacomelli
AGAndrea Gori
Andrea Gori
Pre-exposure prophylaxis (PrEP) is a pivotal intervention among HIV prevention strategies. We aimed to narratively revise the topic of HIV acute infection in the setting of PrEP exposure with a focus on diagnostic options, clinical features, and future PrEP perspectives, with a particular focus on users with high adherence to PrEP. We searched the main databases (PubMed, Embase, and Scopus) with the keywords “PrEP” or “Pre-Exposure Prophylaxis” and “HIV” or “PLWH” and “breakthrough” or “acute infection” or “primary infection”. We included all randomized clinical trials and non-experimental studies (both case reports and observational studies) ever published. In the present narrative review, we revise the diagnostic challenges related to HIV diagnosis in the setting of PrEP and the clinical characteristics and symptoms of breakthrough infections. We discuss the management of acute HIV infection during PrEP and the new challenges that arise from the use of long-acting drugs for PrEP. Our review underlines that although extremely rare, HIV seroconversions are still possible during PrEP, even in a context of high adherence. Efforts to promptly identify these events must be included in the PrEP follow-up in order to minimize the chance of overlooked HIV breakthrough infections and thus exposure to suboptimal concentrations of antiretrovirals.

10 July 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
DCDario Cattaneo
Dario Cattaneo
ATAlessandro Torre
Alessandro Torre
MSMarco Schiuma
Marco Schiuma
ACAurora Civati
Aurora Civati
SLSamuel Lazzarin
Samuel Lazzarin
CGCristina Gervasoni
Cristina Gervasoni
In 2022, we opened an outpatient clinic for the management of polypharmacy and potential drug–drug interactions (pDDIs) in patients with mycobacterial infection (called GAP-MyTB). All patients who underwent a GAP-MyTB visit from March 2022 to March 2023 were included in this retrospective analysis. Fifty-two patients were included in the GAP-MyTB database. They were given 10.4 ± 3.7 drugs (2.8 ± 1.0 and 7.8 ± 3.9 were, respectively, antimycobacterial agents and co-medications). Overall, 262 pDDIs were identified and classified as red-flag (2%), orange-flag (72%), or yellow-flag (26%) types. The most frequent actions suggested after the GAP-MyTB assessment were to perform ECG (52%), therapeutic drug monitoring (TDM, 40%), and electrolyte monitoring (33%) among the diagnostic interventions and to reduce/stop proton pump inhibitors (37%), reduce/change statins (14%), and reduce anticholinergic burden (8%) among the pharmacologic interventions. The TDM of rifampicin revealed suboptimal exposure in 39% of patients that resulted in a TDM-guided dose increment (from 645 ± 101 to 793 ± 189 mg/day, p < 0.001). The high prevalence of polypharmacy and risk of pDDIs in patients with mycobacterial infection highlights the need for ongoing education on prescribing principles and the optimal management of individual patients. A multidisciplinary approach involving physicians and clinical pharmacologists could help achieve this goal.

16 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
CVCarla della Ventura
Carla della Ventura
Stefano MenzoStefano Menzo
Stefano Menzo
BBBianca Bruzzone
Bianca Bruzzone
Gianguglielmo ZehenderGianguglielmo Zehender
Gianguglielmo Zehender
SARS-CoV-2 is constantly evolving leading to new variants. We analysed data from 4,400 SARS-CoV-2-positive samples in order to continue variant surveillance in Italy to evaluate their epidemiological and relative impact on public health in the period April-December 2021. The main circulating strain (76.2%) was Delta followed by Alpha (13.3%), Omicron (5.3%) and Gamma variants (2.9%). B.1.1 lineages, Eta, Beta, Iota, Mu and Kappa variants represented around 1% of cases. Overall, 48.2% of subjects were not vaccinated with a lower median age compared to vaccinated subjects (47 vs. 61 years). An increasing number of infections in vaccinated subjects was observed overtime, with the highest proportion in November (85.2%). Variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed among Delta variant, while subjects harboring Gamma variant showed the highest proportion of asymptomatics (21.6%), albeit also of deaths (5.4%). The Omicron variant was only found in vac-cinated subjects, of which 47% were hospitalized. Diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at national and international level. Our study pro-vides data on the rapid changes in the epidemiological landscape of SARS-CoV-2 variants in Italy.